LON:REDX Redx Pharma (REDX) Share Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free REDX Stock Alerts GBX 18.30 -0.45 (-2.40%) (As of 04:27 PM ET) Add Compare Share Share Today's Range 18▼ 18.9550-Day Range 17.50▼ 2452-Week Range 17▼ 37.90Volume62,901 shsAverage Volume269,244 shsMarket Capitalization£71.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Redx Pharma alerts: Email Address Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Redx Pharma Stock (LON:REDX)Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers. In addition, it is developing RXC009, a potent and selective DDR1 inhibitor, which is in preclinical studies for the treatment of chronic kidney disease; Kirsten rat sarcoma virus (KRAS) inhibitor to target G12D selective and multi-KRAS profiles; RXC006/AZD5055 a porcupine inhibitor, which is in Phase 1 clinical trial for targeting fibrotic diseases, including idiopathic pulmonary fibrosis; JZP815, a pan-rapidly accelerated fibrosarcoma inhibitor that is in Phase 1 clinical trial to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs; and mitogen-activated protein kinase pathway targets for oncology indications. The company has research collaboration agreements with Jazz Pharmaceuticals plc to develop JZP815, as well as discovery and preclinical development of a targeted cancer therapy on the Ras/RAF/MAP kinase pathway; and AstraZeneca plc to develop RXC006/AZD5055, a Porcupine inhibitor for the treatment of fibrotic disease. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.Read More REDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REDX Stock News HeadlinesMarch 8, 2024 | finance.yahoo.comRedx Pharma achieves milestone with dosing of first participant in Phase 1 clinical trial for RXC008February 14, 2024 | marketwatch.comRedx Pharma Says Not Involved in U.S.-Listing ProcessMarch 28, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 14, 2024 | msn.comRedx Pharma denies US listing plan following reportFebruary 13, 2024 | morningstar.comRedx Pharma PLC 0RXFebruary 8, 2024 | finance.yahoo.comJAZZ Boosts Oncology Pipeline With KRAS Inhibitor ProgramFebruary 8, 2024 | finance.yahoo.comRedx Pharma lands biggest deal to date with sale of KRAS inhibitor programme to Jazz PharmaFebruary 7, 2024 | thetimes.co.ukRedx Pharma seals $880m cancer research partnershipMarch 28, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 7, 2024 | lse.co.ukRedx Pharma Share ChatFebruary 7, 2024 | finanznachrichten.deJazz Pharmaceuticals plc: Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor ProgramFebruary 7, 2024 | finance.yahoo.comJazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor ProgramNovember 18, 2023 | finance.yahoo.comRedx Pharma Plc (REDX.L)November 6, 2023 | reuters.comBRIEF-Redx Pharma Unveils Preclinical Data From Rxc009October 20, 2023 | msn.comSMALL CAP MOVERS: Redx Pharma achieves successful £14m fundraiseOctober 19, 2023 | finance.yahoo.comRedx Pharma has "a lot to be excited about" after successful fundraiseOctober 18, 2023 | msn.comRedx Pharma announces plans to raise around £14m to progress pipelineOctober 18, 2023 | lse.co.ukRedx Pharma looks to progress portfolio after raising GBP14.1 millionOctober 18, 2023 | marketwatch.comRedx Pharma Raises GBP14.1 Mln to Progress PipelineOctober 6, 2023 | finance.yahoo.comRedx Pharma's (LON:REDX) investors will be pleased with their impressive 272% return over the last five yearsSeptember 27, 2023 | msn.comAvalyn raises $175m in funding to develop inhaled IPF drugsAugust 29, 2023 | msn.comFDA sees potential in zelasudil for the treatment of idiopathic pulmonary fibrosisAugust 21, 2023 | msn.comMARKET REPORT: Indivior shares rise after £24m Suboxone handoutAugust 21, 2023 | lse.co.ukRedx Pharma says RXC007 receives orphan drug designation from US FDAAugust 21, 2023 | marketwatch.comRedx Pharma Lung Disease Treatment Receives US FDA Orphan Drug DesignationJuly 10, 2023 | lse.co.ukRedx Pharma extends term of outstanding notes with two lenders to 2024May 17, 2023 | marketwatch.comRedx Pharma 1H Pretax Loss Widens on Falling Revenue, Higher CostsSee More Headlines Receive REDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Redx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/19/2018Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:REDX CUSIPN/A CIKN/A Webredxpharma.com Phone+44-151-7064747FaxN/AEmployees101Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-33,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-180.80% Return on Assets-43.95% Debt Debt-to-Equity Ratio527.00 Current Ratio1.11 Quick Ratio1.93 Sales & Book Value Annual Sales£4.20 million Price / Sales16.95 Cash FlowGBX 3.50 per share Price / Cash Flow5.23 Book ValueGBX 1 per share Price / Book18.30Miscellaneous Outstanding Shares388,990,000Free FloatN/AMarket Cap£71.19 million OptionableNot Optionable Beta-0.53 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMs. Lisa Mary Whewell Anson (Age 56)CEO & Executive Director Comp: $608.13kMr. Peter J. CollumChief Financial OfficerDr. James Mead (Age 46)Chief Operating Officer Comp: $132.67kDr. Richard ArmerChief Scientific OfficerDr. Karl Hard Ph.D. (Age 62)Head of Investor Relations Ms. Claire Penelope SolkGeneral Counsel & Company SecretaryMs. Caitlin PearsonHead of CommunicationsDr. Cliff JonesSenior Vice President of Chemistry, DMPK & Intellectual PropertyDr. Caroline PhillipsSenior Vice President of BiologyMr. Craig TilstonHead of Development OperationsMore ExecutivesKey Competitorse-therapeuticsLON:ETXOpen OrphanLON:ORPHMereo BioPharma Group plc (MPH.L)LON:MPHScancellLON:SCLPPoolbeg PharmaLON:POLBView All Competitors REDX Stock Analysis - Frequently Asked Questions How have REDX shares performed in 2024? Redx Pharma's stock was trading at GBX 22 at the start of the year. Since then, REDX shares have decreased by 18.2% and is now trading at GBX 18. View the best growth stocks for 2024 here. How were Redx Pharma's earnings last quarter? Redx Pharma Plc (LON:REDX) issued its quarterly earnings data on Monday, November, 19th. The company reported ($7.00) earnings per share for the quarter, missing the consensus estimate of ($6.50) by $0.50. What other stocks do shareholders of Redx Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Redx Pharma investors own include Digital Globe Services (DGS), OptiBiotix Health (OPTI), TLA Worldwide (TLA), Be Heard Group plc (BHRD.L) (BHRD), Salesforce (CRM), Carnival Co. & (CCL), Burberry Group (BRBY), boohoo group (BOO) and Bank of New York Mellon (BK). How do I buy shares of Redx Pharma? Shares of REDX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:REDX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redx Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.